Gamma-Tocopherol

Gamma-Tocopherol

SCHEMBL8408124

Cc1c(O)cc2c(c1C)O[C@](C)(CCCC(C)CCCC(C)CCCC(C)C)CC2

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 13/20 0.91
PDPK1 O15530 3/20 0.91
PHLPP1 O60346 3/20 0.91
ILK Q13418 3/20 0.91
LMNA P02545 3/20 0.72
MAPT P10636 2/20 0.65
MEN1 O00255 1/20 0.65
GSTP1 P09211 1/20 0.65
TTPA P49638 1/20 0.65
KMT2A Q03164 1/20 0.65
USP2 O75604 1/20 0.65
THRB P10828 1/20 0.65
CYP2C9 P11712 1/20 0.65
CYP2C19 P33261 1/20 0.65
NR1I2 O75469 2/20 0.62
ALOX5 P09917 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gamma-Tocopherol SCHEMBL14695405 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL120346 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL17874900 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL14580952 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL16430717 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL29373100 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL39640 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
SCHEMBL15441242 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL29620131 1.00 AKT1 (0.91) AKT1PDPK1PHLPP1ILKLMNA
Gamma-Tocopherol SCHEMBL28686334 0.99 AKT1 (0.89) AKT1PDPK1PHLPP1ILKLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190192449-A1 COMPOSITION AND USE THEREOF BAYBUTT RICHARD (US) 2019-06-27 US claimed
US-20260014120-A1 COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE NeuviDerm LLC (US) 2026-01-15 US disclosed
US-20250381240-A1 COMPOSITIONS AND METHODS FOR HAIR TREATMENT NEUVIAN SKINCARE LLC (US) 2025-12-18 US disclosed
US-20250339545-A1 ANTIOXIDANT COMPOSITIONS AND METHODS LEUVIAN LLC (US) 2025-11-06 US disclosed
US-20250281563-A1 COMPOSITIONS AND METHODS FOR HAIR TREATMENT NEUVIAN IP HOLDINGS, LLC 2025-09-11 US disclosed
US-12409204-B1 Compositions and methods for hair treatment NEUVIAN IP HOLDINGS, LLC (US) 2025-09-09 US disclosed
US-12377156-B2 Compositions and methods for treatment of wounds and inflammatory skin conditions NEUVIAN IP HOLDINGS, LLC (US) 2025-08-05 US disclosed
WO-2025090117-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONS LEUVIAN, LLC (US) 2025-05-01 WO disclosed
US-20250127911-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONS NEUVIAN IP HOLDINGS, LLC 2025-04-24 US disclosed
US-20230338309-A1 COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONS JSS RESEARCH, LLC 2023-10-26 US disclosed
US-20140221674-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES EDISON PHARMACEUTICALS, INC. (US) 2014-08-07 US disclosed
US-8575369-B2 Process for the production of alpha-tocotrienol and derivatives EDISON PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575369-B2 Process for the production of alpha-tocotrienol and derivatives EDISON PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-20120130093-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES PTC THERAPEUTICS, INC. 2012-05-24 US disclosed
US-20120130093-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES PTC THERAPEUTICS, INC. 2012-05-24 US disclosed
US-8106223-B2 Process for the production of alpha-tocotrienol and derivatives EDISON PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106223-B2 Process for the production of alpha-tocotrienol and derivatives EDISON PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
WO-2010051277-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES EDISON PHARMACEUTICALS, INC. (US) 2010-05-06 WO disclosed
US-20100105930-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES PTC THERAPEUTICS, INC. 2010-04-29 US disclosed
US-20100105930-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES PTC THERAPEUTICS, INC. 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12409204-B1 Compositions and methods for hair treatment AOC1, SOD3, OAT AKT1 3895/4885PDPK1 3933/4885PHLPP1 2327/4885
US-12377156-B2 Compositions and methods for treatment of wounds and inflammatory skin conditions SOD3, SOD1, CUTA AKT1 2405/4885PDPK1 2892/4885PHLPP1 2346/4885
US-20250127911-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS AND INFLAMMATORY SKIN CONDITIONS SOD3, SOD1, CUTA AKT1 2405/4885PDPK1 2892/4885PHLPP1 2346/4885
US-20250339545-A1 ANTIOXIDANT COMPOSITIONS AND METHODS SOD1, SOD3, LPO AKT1 2286/4885PDPK1 2212/4885PHLPP1 2558/4885
US-20140221674-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES TTPA, LCAT, PCTP AKT1 4031/4885PDPK1 1773/4885PHLPP1 4780/4885
US-20120130093-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES TTPA, LCAT, PCTP AKT1 4031/4885PDPK1 1773/4885PHLPP1 4780/4885
US-20250281563-A1 COMPOSITIONS AND METHODS FOR HAIR TREATMENT AOC1, SOD3, OAT AKT1 3895/4885PDPK1 3933/4885PHLPP1 2327/4885
US-20190192449-A1 COMPOSITION AND USE THEREOF RXRG, RARG, TTPA AKT1 3762/4885PDPK1 4376/4885PHLPP1 4209/4885
US-20100105930-A1 PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES TTPA, LCAT, PCTP AKT1 4031/4885PDPK1 1773/4885PHLPP1 4780/4885
US-20260014120-A1 COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF SALTS OF CARNOSINE AND CARNITINE CRAT, CCR10, SLC25A20 AKT1 2074/4885PDPK1 2489/4885PHLPP1 2030/4885
US-20250381240-A1 COMPOSITIONS AND METHODS FOR HAIR TREATMENT AOC1, SOD3, OAT AKT1 3895/4885PDPK1 3933/4885PHLPP1 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.